A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To evaluate disease control rate (DCR) of S-1 in combination with gemcitabine in patients
with advanced biliary tract cancer
Secondary Objectives:
- To evaluate overall response rate (ORR)
- To evaluate progression-free survival (PFS)
- To evaluate overall survival (OS)
- To assess the safety profile
Phase:
Phase 2
Details
Lead Sponsor:
TTY Biopharm
Collaborators:
Chang Gung Memorial Hospital National Cheng-Kung University Hospital National Taiwan University Hospital Taipei Veterans General Hospital, Taiwan